Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva

Gynecologic Oncology Group515 enrolled

Overview

RATIONALE: Lymphatic mapping may improve the ability to detect cancer of the vulva. PURPOSE: This phase III trial is studying how well lymphatic mapping works in treating patients with stage I or stage II cancer of the vulva.

OBJECTIVES: * Determine the negative predictive value of a negative sentinel lymph node in patients with invasive squamous cell carcinoma of the vulva. * Determine the location of the sentinel node in these patients. OUTLINE: Patients receive injection(s) of isosulfan blue into the dermis at the junction of the tumor and normal vulvar skin. Once the afferent lymphatic channel and sentinel node have been identified, patients undergo unilateral or bilateral inguinal-femoral lymphadenectomy followed by resection of the primary tumor with adequate margins. Preoperative lymphoscintigraphy is also performed. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter or until recurrence. PROJECTED ACCRUAL: A total of 40-630 patients will be accrued for this study within 2-6 years.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

515

Conditions

Vulvar Cancer

Interventions

Sentinel lymph node mappingPROCEDURE

Sentinel lymph node mapping

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Histologically confirmed invasive squamous cell carcinoma of the vulva that is greater than 1 mm in thickness as measured from the nearest rete peg * Tumor size must be 2-6 cm * No recurrent disease * Prior excision of the primary disease or a history of carcinoma in situ of the vulva allowed * No tumor extending into the urethra, anus, vagina, rectum, or bladder * No grossly suspicious or inflamed groin nodes on physical exam * No grossly infected primary tumors PATIENT CHARACTERISTICS: Age: * Any age Performance status: * GOG 0-3 Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Other: * No other invasive malignancy within the past 5 years except non-melanomatous skin cancer * No known hypersensitivity to phenylethane compounds PRIOR CONCURRENT THERAPY: * No prior cancer therapy that contraindicates therapy in this study Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * See Disease Characteristics * No prior groin dissection

Locations (72)

Outcomes

Primary Outcomes

Predictive value of negative sentinel lymph nodes in vulvar cancer patients

Time frame: at time of surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Todd Cancer Institute at Long Beach Memorial Medical Center

Long Beach, California, United States

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, United States

Helen and Harry Gray Cancer Center at Hartford Hospital

Hartford, Connecticut, United States

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

Hartford, Connecticut, United States

George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus

New Britain, Connecticut, United States

Washington Cancer Institute at Washington Hospital Center

Washington D.C., District of Columbia, United States

Mayo Clinic - Jacksonville

Jacksonville, Florida, United States

Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center

Savannah, Georgia, United States

Hinsdale Hematology Oncology Associates

Hinsdale, Illinois, United States

...and 62 more locations